去甲基化剂在急性髓系白血病中的临床应用及研究进展
| 作者: |
1陈文佳,
1,2李英花
1 哈尔滨医科大学附属第一医院血液科，哈尔滨 150000 2 黑龙江省医学科学院，哈尔滨 150081 |
| 通讯: |
李英花
Email: liyinghua1965@aliyun.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.07.036 |
| 基金: | 黑龙江省科研计划项目 (201708)。 |
摘要
急性髓系白血病(acute myelo id leukemia，AML)是一种临床和遗传异质性疾病且预后不良。基因组学和分子生物学的最新进展使得对该疾病有了进一步的了解。作为单一药物，去甲基化剂(hypomethylating agents，HMA s)仅可诱导15%~25%的完全缓解率，但目前的数据表明，在使用HMAs后观察到的中位总生存期(overall sur vival，OS)与强化治疗后观察到的中位OS相当。一些接受HMAs治疗的患者是否可获得长期生存尚不清楚。HMAs与新药的结合现已得到广泛研究，且取得了相当好的疗效。
关键词：
去甲基化剂；表观遗传学；急性髓系白血病
Clinical application and progress of demethylating agents in acute myeloid leukemia
CorrespondingAuthor: LI Yinghua Email: liyinghua1965@aliyun.com
DOI: 10.3978/j.issn.2095-6959.2019.07.036
Foundation: This work was supported by the Scientific Research Project of Heilongjiang Province, China (201708).
Abstract
Acute myeloid leukemia (AML) is a clinical and genetic heterogeneous disease with poor prognosis. Recent advances in genomics and molecular biology have led to a better understanding of the disease. The hypomethylating agents (HMAs) only induced a complete response rate of 15% to 25%. Current data show that the median overall survival observed after HMAs is comparable to that observed after intensive therapy. It is not clear whether patients who receiving HMAs therapy can achieve long-term survival. The combination of HMAs and new drugs has been extensively studied, and a large number of reports have been reported on the combination of HMAs and different drugs for AML, and achieved fairly good results.
Keywords：
hypomethylating agents; epigenetics; acute myeloid leukemia